Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback